Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria
Open accessThe DOI matches its Crossref record.
Abstract
Dihydroartemisinin-piperaquine (DHP) is an important new treatment for drug-resistant malaria, although pharmacokinetic studies on the combination are limited. In Papua, Indonesia, we assessed determinants of the therapeutic efficacy of DHP for uncomplicated malaria. Plasma piperaquine concentrations were measured on day 7 and day 28, and the cumulative risk of parasitological failure at day 42 was calculated using survival analysis. Of the 598 patients in the evaluable population 342 had infections with Plasmodium falciparum , 83 with Plasmodium vivax , and 173 with a mixture of both species. The unadjusted cumulative risks of recurrence were 7.0% (95% confidence interval [CI]: 4.6 to 9.4%) for P. falciparum and 8.9% (95% CI: 6.0 to 12%) for P. vivax . After correcting for reinfections the risk of recrudescence with P. falciparum was 1.1% (95% CI: 0.1 to 2.1%). The major determinant of parasitological failure was the plasma piperaquine concentration. A concentration below 30 ng/ml on day 7 was observed in 38% (21/56) of children less than 15 years old and 22% (31/140) of adults ( P = 0.04), even though the overall dose (mg per kg of body weight) in children was 9% higher than that in adults ( P < 0.001). Patients with piperaquine levels below 30 ng/ml were more likely to have a recurrence with P. falciparum (hazard ratio [HR] = 6.6 [95% CI: 1.9 to 23]; P = 0.003) or P. vivax (HR = 9.0 [95% CI: 2.3 to 35]; P = 0.001). The plasma concentration of piperaquine on day 7 was the major determinant of the therapeutic response to DHP. Lower plasma piperaquine concentrations and higher failure rates in children suggest that dose revision may be warranted in this age group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
van der Pluijm, R. W., Imwong, M., Chau, N. H., Hoa, N. T., Thuy-Nhien, N. T., Thanh, N. V., Jittamala, P., Hanboonkunupakarn, B., Chutasmit, K., Saelow, C., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30391-3 · Cited by 386
New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance
Price, R. N., Douglas, N. M., & Anstey, N. M. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32832f14c1 · Cited by 343
Self-citationLeang, R., Taylor, W. R. J., Bouth, D. M., Song, L., Tarning, J., Char, M. C., Kim, S., Witkowski, B., Duru, V., Domergue, A., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00835-15 · Cited by 302
Resistance to Therapies for Infection by Plasmodium vivax
Baird, J. K. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-09 · Cited by 262
Rijken, M. J., McGready, R., Phyo, A. P., Lindegardh, N., Tarning, J., Laochan, N., Than, H. H., Mu, O., Win, A. K., Singhasivanon, P., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05067-11 · Cited by 75
Metadata
- Authors
- Price, R. N., Hasugian, A. R., Ratcliff, A., Siswantoro, H., Purba, H. L. E., Kenangalem, E., Lindegardh, N., Penttinen, P., Laihad, F., Ebsworth, E. P., Anstey, N. M., & Tjitra, E.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2007-11
- Volume
- 51
- Issue
- 11
- Pages
- 4090-4097
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2061999977
- Cited by
- 97
- References
- 0
- FWCI
- 8.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria. https://app.cochat.ai/papers/10.1128/aac.00486-07
- The paper
- Price, R. N., Hasugian, A. R., Ratcliff, A., Siswantoro, H., Purba, H. L. E., Kenangalem, E., Lindegardh, N., Penttinen, P., Laihad, F., Ebsworth, E. P., Anstey, N. M., & Tjitra, E. (2007). Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00486-07
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.